65,437 trials
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Progression-free Survival (PFS) at 6 Months — 25; 7.7 percentage of participants
Anemia, Neoplasms
Primary: Percentage of Participants With Early Treatment Response: Day 28 to 42 — 52.4; 56.5; 53.8 percentage of participants
Diabetes Mellitus Type 2
Primary: Hypoglycemic Profile of Vildagliptin Compared to Sitagliptin Over 4 Days After 8 Weeks of Treatment in Period 1 & 2 — 11.2; 5.3 mmol/L/4d
Benign Biliary Strictures
Primary: Short Term Success Rate in the Resolution of Biliary Strictures — 22; 14; 3; 5 participants
Major Depressive Disorder Without Psychotic Features
Primary: Change in MADRS Total Score — -14.29; -11.61 units on a scale
Rheumatoid Arthritis
Primary: EULAR Good Response — 33.3; 52.1 percentage of responders
Colorectal Neoplasms
Primary: Detection Rates for Adenomas and for Total Polyps — 160; 163; 78; 31 Polyps or adenomas detected
Colorectal Cancer
Primary: Percentage of Participants With Conversion From Unresectable to Resectable Liver Metastases — 42.2 percentage of participants
Hyperlipidemia
Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 — 2.76; -0.98; -39.06; -57.48 percent change — p=<0.001
Gastric Cancer
Primary: Percentage of Participants With Disease-free Survival (DFS) at Month 18 — 76.12 percentage of participants
Cystic Fibrosis
Primary: Blood-plasma Concentration of Piperacillin — 21; 21 mg/L
Follicular Lymphoma
Primary: Number of Participants With an Adverse Event (AE), Serious AE, or Death Related to AE — 34; 10; 7 participants
Cirrhosis · Hepatic Encephalopathy
Primary: Part A: The Rate of AEs and Tolerability of HPN-100 — 11; 9; 7; 4 Subjects
Solid Tumor
Primary: Maximum Tolerated Dose (MTD) of the Combination of Pertuzumab and Capecitabine — 1250 mg/m^2
Hepatitis C
Primary: Number of Participants Who Completed Standard Treatment — 10; 0 participants